Ensysce Biosciences, Inc. - 10-Q Filing
Ensysce Biosciences reports Q3 2026 results including Series C preferred stock issuance and clinical trial milestone activity.
Tickers: $ENSC
Read the full article at SEC EDGAR
Part of the story Avalyn Pharma Inc. - 10-Q Filing (4 articles)